Home>Topics>Companies>Ranbaxy Laboratories

Ranbaxy Laboratories

  1. All
  2. Commentary
  3. Headlines
  1. Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic -CEO

    Headlines

    Tue, 28 Oct 2014

    MUMBAI, Oct 28 (Reuters) - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite...

  2. SNAPSHOT-India stocks, bonds, rupee, swap, call at close

    Headlines

    Tue, 28 Oct 2014

    The benchmark BSE index ended up 0.48 percent and the broader NSE index closed 0.45 percent higher, as drugmakers got a shot in the arm after Ranbaxy Laboratories Ltd reported its first profit in six quarters.

  3. UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

    Headlines

    Tue, 28 Oct 2014

    * Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

  4. India's Ranbaxy posts Q2 profit

    Headlines

    Tue, 28 Oct 2014

    MUMBAI, Oct 28 (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd , which is in the process of being acquired by larger rival Sun Pharmaceutical Industries Ltd , reported a profit in its second quarter.

  5. INDIA PRESS- Ranbaxy may lose heartburn drug Nexium exclusivity - Business Standard

    Headlines

    Sun, 26 Oct 2014

    Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aditya Kondalamahanty in Bangalore)

  6. INDIA PRESS- Ranbaxy staff get pay-cut shield in Sun buyout - Business Standard

    Headlines

    Sun, 19 Oct 2014

    Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

  7. Merck and Ranbaxy settle Medicaid suits

    Headlines

    Thu, 16 Oct 2014

    indications. Merck acquired Organon as part of its takeover of Schering-Plough in 2009. Indian generic firm Ranbaxy Laboratories ( OTC:RBXLY ) agrees to pay almost $40M to Texas to resolve allegations that it violated the Medicaid Fraud

  8. UPDATE 1-India's Ranbaxy to pay $40 mln to settle Texas Medicaid pricing litigation

    Headlines

    Thu, 16 Oct 2014

    * Ranbaxy shares up 0.6 percent in Mumbai (Adds settlement details, analyst views, updates share price)

  9. India's Ranbaxy to pay $40 mln to settle Texas Medicaid pricing litigation

    Headlines

    Thu, 16 Oct 2014

    MUMBAI, Oct 16 (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd said it had agreed to pay $39.75 million to settle litigations concerning its participation in Texas Medicaid, the US federal-state healthcare program for the poor.

  10. INDIA PRESS- Ranbaxy's US subsidiary sees 5 top-level exits - Economic Times

    Headlines

    Mon, 13 Oct 2014

    Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

« Prev1234Next »
Content Partners